View of Preclinical Evaluation of HPV Type 52 L1L2 Chimeric Protein as a Cervical Cancer Vaccine Candidate

Return to Article Details Preclinical Evaluation of HPV Type 52 L1L2 Chimeric Protein as a Cervical Cancer Vaccine Candidate Download Download PDF